Vincent Ossipow
Net worth: 4 M $ as of 2026-09-29
Net worth: 4 M $ as of 2026-09-29
Dr. Vincent Ossipow is a Partner at NeoMed S.à.r.l., an Independent Non-Executive Director at SOPHiA GENETICS SA and a Partner at Omega Fund Management LLC.
He is on the Board of Directors at FoRx Therapeutics AG, SOPHiA GENETICS SA and Immunic AG.
Dr. Ossipow was previously employed as a Chief Scientific Officer by Omega Alpha SPAC, an Independent Director by Immunic, Inc., an Independent Director by BioInvent International AB, a Partner & Financial Advisor by Covalence SA (Switzerland), a Partner by Omega Funds, a Co-Manager by Pictet - Biotech, a Research Analyst by Pictet Bank & Trust Ltd. (Private Banking), and an Investment Manager by Sectoral Asset Management, Inc. (Switzerland).
He also served on the board at Vital Therapies, Inc., eTheRNA immunotherapies NV, Kuros Biosciences Ltd., Aerium Therapeutics, Inc., Andrew Alliance SA, Lifespan, Inc., Luxe Trading SA and RainDance Technologies, Inc. He received his doctorate degree from the University of Geneva.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SOPHIA GENETICS SA 0.61% | 2026-06-17 | 522,860 ( 0.61% ) | 4 M $ | 2026-09-29 |
| Companies | Position | Start |
|---|---|---|
| SOPHIA GENETICS SA | Director/Board Member | 2014-05-31 |
NeoMed S.à.r.l.
NeoMed S.à.r.l. Investment ManagersFinance Functions as an alternative investment manager | Private Equity Investor | 2016-12-31 |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops cancer treatment compounds | Director/Board Member | 2019-09-30 |
Immunic AG
Immunic AG Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals in the immunology space | Director/Board Member | - |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management invests in private and public companies located in the United States and Europe. The firm focuses on sectors such as biotechnology, life sciences, healthcare and medical devices. It provides financing for seed, early, mid and later stage capital requirements. The firm also makes follow-on investments | Private Equity Investor | 2014-03-31 |
| Companies | Position | End |
|---|---|---|
| IMMUNIC, INC. | Director/Board Member | 2023-06-27 |
| KUROS BIOSCIENCES AG | Director/Board Member | 2016-04-30 |
Sectoral Asset Management, Inc. (Switzerland)
Sectoral Asset Management, Inc. (Switzerland) Investment ManagersFinance Sectoral is a fundamentals-based, medium- to long-term, GARP-oriented manager which focuses on companies in the healthcare (Pharmaceuticals, Generics, Biotechs and Medtechs) sector. They aim to achieve superior returns for investors by concentrating on primary research. The firm conducts preliminary research and analysis, including literature and documentation, interaction with companies and with Sectoral's Advisory Network, to identify investment candidates. They then conduct forecasting and scenario analyses, testing a range of assumptions and success factors critical to the company's success. They subsequently generate realistic valuation ranges for potential investments and assess the impact of the investment on the overall risk/return profile of the portfolio. They believe that specific risk is the most important risk component and have developed and refined their investment process to mitigate it. Their analysts attempt to determine the fair value for investment candidates as well as 1-year and 3-year price targets. Depending on the development stage of the company, they utilize models such as discounted cash-flow models, EBITDA models, classical growth models (PE approach), enterprise value/sales and peer group analysis to determine the price targets. Sectoral makes recommendations based on the resulting fair value to the current market value of each investment candidate and constructs portfolios comprised of analysts' investment recommendations. Their CIO determines the weight of each industry based on the attractiveness of expected growth, profitability, historic valuation and relative valuation. | Director/Board Member | 2012-12-31 |
Omega Funds
Omega Funds Investment Trusts/Mutual FundsMiscellaneous Open-End Investment Fund/Unit Trust | Corporate Officer/Principal | - |
| ░░░░░░░░░ ░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ ░ ░░░░░░░ | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 22 |
|---|---|
Lifespan, Inc.
Lifespan, Inc. Medical/Nursing ServicesHealth Services Provides healthcare services | Health Services |
RainDance Technologies, Inc.
RainDance Technologies, Inc. Medical SpecialtiesHealth Technology Develops and commercializes professional laboratory system | Health Technology |
Omega Funds
Omega Funds Investment Trusts/Mutual FundsMiscellaneous Open-End Investment Fund/Unit Trust | Miscellaneous |
Pictet - Biotech
Pictet - Biotech Investment Trusts/Mutual FundsMiscellaneous Acts as Open-End Investment Fund/Unit Trust | Miscellaneous |
BioInvent International AB
BioInvent International AB BiotechnologyHealth Technology Develops and manufactures immunomodulatory antibodies for cancer treatment | Health Technology |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotherapeutic company focused on developing a cell-based therapy | Health Technology |
University of Geneva
University of Geneva Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NeoMed S.à.r.l.
NeoMed S.à.r.l. Investment ManagersFinance Functions as an alternative investment manager | Finance |
Sectoral Asset Management, Inc. (Switzerland)
Sectoral Asset Management, Inc. (Switzerland) Investment ManagersFinance Sectoral is a fundamentals-based, medium- to long-term, GARP-oriented manager which focuses on companies in the healthcare (Pharmaceuticals, Generics, Biotechs and Medtechs) sector. They aim to achieve superior returns for investors by concentrating on primary research. The firm conducts preliminary research and analysis, including literature and documentation, interaction with companies and with Sectoral's Advisory Network, to identify investment candidates. They then conduct forecasting and scenario analyses, testing a range of assumptions and success factors critical to the company's success. They subsequently generate realistic valuation ranges for potential investments and assess the impact of the investment on the overall risk/return profile of the portfolio. They believe that specific risk is the most important risk component and have developed and refined their investment process to mitigate it. Their analysts attempt to determine the fair value for investment candidates as well as 1-year and 3-year price targets. Depending on the development stage of the company, they utilize models such as discounted cash-flow models, EBITDA models, classical growth models (PE approach), enterprise value/sales and peer group analysis to determine the price targets. Sectoral makes recommendations based on the resulting fair value to the current market value of each investment candidate and constructs portfolios comprised of analysts' investment recommendations. Their CIO determines the weight of each industry based on the attractiveness of expected growth, profitability, historic valuation and relative valuation. | Finance |
Covalence SA (Switzerland)
Covalence SA (Switzerland) Investment ManagersFinance Provides investment research | Finance |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management invests in private and public companies located in the United States and Europe. The firm focuses on sectors such as biotechnology, life sciences, healthcare and medical devices. It provides financing for seed, early, mid and later stage capital requirements. The firm also makes follow-on investments | Finance |
Pictet Bank & Trust Ltd. (Private Banking)
Pictet Bank & Trust Ltd. (Private Banking) Investment ManagersFinance Profile Unavailable. | Finance |
SOPHiA GENETICS SA
SOPHiA GENETICS SA Packaged SoftwareTechnology Services Develops software services for healthcare industry | Technology Services |
Kuros Biosciences Ltd.
Kuros Biosciences Ltd. Medical SpecialtiesHealth Technology Manufactures medical device technology and provides clinical research development services | Health Technology |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics | Health Technology |
Andrew Alliance SA
Andrew Alliance SA Industrial MachineryProducer Manufacturing Develops and markets novel liquid handling robots to enhance the reproducibility and the efficiency of the pipetting process | Producer Manufacturing |
Immunic AG
Immunic AG Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals in the immunology space | Health Technology |
Immunic, Inc.
Immunic, Inc. Pharmaceuticals: MajorHealth Technology Develops oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases | Health Technology |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops cancer treatment compounds | Health Technology |
Omega Alpha SPAC
Omega Alpha SPAC Financial ConglomeratesFinance Operates as a blank check company | Finance |
Luxe Trading SA | |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery & development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic & pandemic threats | Commercial Services |
Select your edition
All financial news and data tailored to specific country editions